CCL2 and neoplasm: Tumor-derived IL-6 induces endothelial IL6-STAT3 signaling, which in turn may lead to increased plasma concentrations of cachexia-promoting factors like C-C motif chemokine ligand 2 (CCL2/MCP-1), commonly described in CAC patients (86, 87).